The company's stock took a hit after the investment firm downgraded it to "underweight" from "neutral."
R.W. Baird, the Cowen Group, Jefferies, and UBS each recommended Complete Genomics' stock with target share prices significantly above the company's current trading price.
The investment firm noted the "enormous" market opportunity for Exact Sciences' Cologuard test and predicted it would receive FDA clearance in 2013.
All of the banks issued favorable recommendations on the molecular diagnostics firm's stock.
The bank also placed a price target of $52 on Illumina's stock.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.
DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.
The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.
In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.